Month: March 2025

OSLO, Norway (21 March 2025) – TGS, a leading global provider of energy data and intelligence, published its 2024 annual report today.  In addition, TGS has published its 2024 Management Remuneration Report (MRR) according to the Norwegian Public Limited Liability Companies Act, section 6-16b (2). The 2024 annual report and the MRR are available on the TGS’ website https://www.tgs.com. The Annual Report has also been published in European Single Electronic Format (ESEF) and can be downloaded from TGS.com (http://www.tgs.com) or www.newsweb.no.About TGSTGS provides advanced data and intelligence to companies active in the energy sector. With leading-edge technology and solutions spanning the entire energy value chain, TGS offers a comprehensive range of insights to help clients make better decisions. Our broad range of products...

FORM 8.5 (EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)        Name of exempt principal trader: Investec Bank plc(b)        Name of offeror/offeree in relation to whose relevant securities this form relates:         Use a separate form for each offeror/offeree Niox Group plc(c)        Name of the party to the offer with which exempt principal trader is connected: Investec is Joint Broker to Niox Group plc(d)        Date dealing undertaken: 20th March 2025(e)        In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to this offer?         If it is a cash offer or possible cash offer, state...

CHANDLER, Ariz., March 21, 2025 (GLOBE NEWSWIRE) — (NASDAQ: MCHP) Microchip Technology Incorporated (“Microchip” or the “Company”), a leading provider of smart, connected, and secure embedded control solutions, today announced the pricing of its previously announced underwritten public offering of $1.35 billion of depositary shares (“depositary shares”), each representing a 1/20th interest in a share of newly issued 7.50% Series A Mandatory Convertible Preferred Stock, par value $0.001 per share (“preferred stock”) at a public offering price of $50.00 per depositary share (the “offering”). Microchip granted the underwriters in the offering a 13-day option to purchase up to an additional $135 million of depositary shares, solely to cover over-allotments, if any, at the public offering price less the underwriting discount. The offering...

VANCOUVER, British Columbia, March 20, 2025 (GLOBE NEWSWIRE) — Vortex Energy Corp. (CSE: VRTX | OTC: VTECF | FRA: AA3) (“Vortex” or the “Company”) announces a proposed consolidation of the common shares of the Company (the “Common Shares”) on the basis of ten (10) pre-consolidation Common Shares for one (1) post-consolidation Common Share (the “Consolidation”). The Company currently has 82,810,561 Common Shares issued and outstanding, and following the Consolidation, will have approximately 8,281,056 Common Shares issued and outstanding, prior to rounding of fractional Common Shares. No fractional Common Shares will be issued as a result of the proposed Consolidation. Any fractional Common Shares resulting from the proposed Consolidation will be rounded up in the case of a fractional interest that is one-half (1/2) of a Common...

Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G)Phase III study showed sustained proteinuria reduction at one year with favorable safety1 Fabhalta is the only oral alternative complement pathway inhibitor thought to target the underlying cause of C3G1-3 C3G is an ultra-rare kidney disease typically diagnosed in young adults and often progresses to kidney failure2-4 Novartis continues to advance multiple kidney disease treatments with high unmet need, compounding capabilities and strengthening unique leadership presenceBasel, March 20, 2025 – Novartis today announced that oral Fabhalta® (iptacopan) has received U.S. Food and Drug Administration (FDA) approval for the treatment of adults with C3 glomerulopathy (C3G), to reduce proteinuria, making it...

ZUG, Switzerland, March 20, 2025 (GLOBE NEWSWIRE) — The attached notifications relate to trades entered into by a PDMR of the Company pursuant to a 10b5-1 trading plan, in accordance with Rule 10b5-1(c)(1) of the Securities Exchange Act of 1934, as amended.AttachmentsPDMR notification – R. Sherif – sales 14 Mar 2025PDMR notification – R. Sherif – sales 17 Mar 2025PDMR notification – R. Sherif – sales 18 Mar 2025PDMR notification – R. Sherif – sales 19 Mar 2025PDMR notification – R. Sherif – sales 20 Mar 2025